Emergent BioSolutions (NYSE:EBS) Shares Down 3.9% – Should You Sell?

Emergent BioSolutions Inc. (NYSE:EBS) dropped 3.9% during mid-day trading on Tuesday . The company traded as low as $10.78 and last traded at $10.75. Approximately 113,481 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 992,138 shares. The stock had previously closed at $11.19.

Wall Street Analysts Forecast Growth

EBS has been the topic of a number of research analyst reports. Benchmark boosted their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, November 7th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a report on Tuesday, January 21st. Finally, StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Friday.

Emergent BioSolutions Price Performance

The company has a market capitalization of $591.65 million, a price-to-earnings ratio of -2.66 and a beta of 1.60. The stock has a fifty day simple moving average of $9.39 and a 200-day simple moving average of $9.31. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Emergent BioSolutions (NYSE:EBS) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $1.37 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.88. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The firm had revenue of $293.80 million for the quarter, compared to analysts’ expectations of $328.72 million. During the same period last year, the firm earned ($1.44) EPS. On average, equities research analysts anticipate that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of EBS. State Street Corp boosted its holdings in shares of Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock worth $15,960,000 after purchasing an additional 1,713,200 shares during the last quarter. Oak Hill Advisors LP purchased a new position in Emergent BioSolutions during the third quarter worth about $9,296,000. Millennium Management LLC boosted its holdings in Emergent BioSolutions by 5.8% in the 2nd quarter. Millennium Management LLC now owns 946,302 shares of the biopharmaceutical company’s stock valued at $6,454,000 after purchasing an additional 52,144 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Emergent BioSolutions by 3.4% in the 4th quarter. Assenagon Asset Management S.A. now owns 766,537 shares of the biopharmaceutical company’s stock valued at $7,328,000 after buying an additional 24,985 shares during the period. Finally, Geode Capital Management LLC increased its holdings in shares of Emergent BioSolutions by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 581,958 shares of the biopharmaceutical company’s stock worth $4,861,000 after buying an additional 25,776 shares during the last quarter. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.